Clinical trial · Observational
Screening for High Frequency Malignant Disease
NCT05117840CI-TRIAL-00116814SHIELDactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low-dose CT scan | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lung Cancer Screening Cohort
- description
- Individuals at high-risk of lung cancer undergoing standard of care screening as per USPSTF guidelines. All subjects will undergo low-dose CT scanning as per guidelines and an investigational blood-draw will be taken from all enrolled subjects.
- interventionNames
- Device: Low-dose CT scan
Primary outcomes (1)
- measure
- Performance characteristics of Guardant LUNAR-2 test
- timeFrame
- 36 months
- description
- Sensitivity, specificity, NPV, PPV
Secondary outcomes (1)
- measure
- Screen detected cancer rate
- timeFrame
- 36 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects aged 50-80 years at time of consent * Increased risk of lung cancer defined by: at least 20 pack-year smoking history and currently smoke or have quit within the past 15 years * Undergoing or intended to undergo low dose CT scan of the chest for lung cancer screening * Willing to consent to the investigational blood draw during index LDCT screening visit and before any invasive procedures or treatment for lung cancer diagnosis * Willing to consent to a 1-year and additional follow-up per protocol Exclusion Criteria: 1. Subject has quit smoking for 15 or more years 2. Subject has less than 20 pack-year smoking history 3. Subject has a health problem that substantially limits life expectancy and/or the ability or willingness to have curative lung surgery 4. Subject undergoing low-dose CT scan of the chest for investigation of symptoms suspicious for lung cancer 5. Preexisting or history of lung cancer 6. Previously diagnosed high-risk lung lesion 7. History of any malignancy (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study) 8. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs 9. Currently receiving treatment for pneumonia 10. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent 11. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study 12. Participation in a clinical research study in which an experimental medication and/or medical procedure has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of subject screening
References
Publications (0)
Data not yet available
No reference posted for this study.